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Abstract Since the arrival of Translational Medicine (TM), as both a term and 
movement in the late 1990s, it has been associated almost exclusively with attempts 
to accelerate the “translation” of research-laboratory findings to improve efficacy 
and outcomes in clinical practice (Krueger et  al. in Hist Philos Life Sci 41:57, 
2019). This framing privileges one source of change in medicine, that from bench-
to-bedside. In this article we dig into the history of translation research to identify 
and discuss three other types of translational work in medicine that can also reshape 
ideas, practices, institutions, behaviours, or all of these, to produce transformations 
in clinical effectiveness. These are: (1) making accessible state-of-the-art knowledge 
and best practice across the medical profession; (2) remodelling and creating institu-
tions to better develop and make available specialist knowledge and practice; and (3) 
improving public and patient understandings of disease prevention, symptoms and 
treatments. We do so by examining the work of William S. C. Copeman, a dominant 
figure in British rheumatology from the 1930 through the late 1960s. Throughout 
his long career, Copeman blended approaches to “translation” in order to produce 
transformative change in clinical medicine, making his work an exemplar of our 
expanded notion of TM.
Keywords Translation medicine · William Copeman · Rheumatology · Medical 
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1 Introduction
Since the arrival of Translational Medicine (TM) as both a term and movement in 
the late 1990s, it has been associated almost exclusively with attempts to accelerate 
the “translation” of research-laboratory discoveries into clinical applications (Krue-
ger et  al. 2019). Many discussions of TM assume a linear model, where “innova-
tion starts with basic research, is followed by applied research and development, 
and ends with production and diffusion” (Godin 2006). One reason this model 
dominates is its applicability to pharmaceutical research and the goal of shorten-
ing, speeding up, or unblocking the “pipeline” of new chemical entities (NCEs) 
becoming approved drugs (Butler 2008). Observers and analysts have convention-
ally framed TM as a four stage process: T1—basic research to produce innovations 
with therapeutic potential, T2—development of clinical trials, T3—clinical imple-
mentation and uptake, T4—assessment of outcomes and effectiveness (Sung et al. 
2003; Woolf 2008; Fort et al. 2017). But despite this initial framing, empirical stud-
ies have demonstrated the complexity of interactions between stages and that a fully 
linear process is rare. Historians’ studies of other areas of medical innovation have 
long shown that the same messiness applies (Pickstone 1992). Indeed, it is more 
normal for laboratory discoveries to “fail” to be translated into clinical practice, as 
demonstrated by the very low number of NCEs that become marketable drugs. Even 
when an NCE “succeeds”, the extent of its adoption and use will vary, as new drugs 
largely compete with other new therapies.
The point about “failed” innovations is a valuable counter to a common feature of 
studies of TM—namely, that they are teleological. Not only do they focus on “win-
ners,” but the paths to success they describe can appear predetermined. However, 
in this study, we want to use one aspect of the teleological view constructively, to 
explore an expanded notion of TM, with TM referring not only to a means or pro-
cess, but also to an end or outcome. In other words, a central goal of TM is trans-
forming clinical practice and effectiveness. Highlighting this goal-oriented aspect 
raises the question: What of the other means of achieving the same end? In this 
article we discuss three other “translational” and “transformational” means: (1) 
Making available state-of-the-art, specialist knowledge and best practice to groups 
across medicine; (2) Creating or remodelling institutions to promote and develop 
knowledge and innovative practices; and (3) Developing ways to improve public 
and patient knowledge about disease prevention, symptoms and treatments. In the 
case we discuss below, all three routes involved translations of ideas, practices, insti-
tutions, behaviours, even all of these at once. Ideas were changed to work in new 
contexts and with new audiences, while practices were reworked to be effective in 
the hands of different groups. Institutions were remodelled to be more effective in 
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achieving clinical outcomes, and professionals’ behaviours were modified to prevent 
disease or better manage treatments and aftercare.
The clinical area in which we develop our analysis is the treatment of patients 
with rheumatic diseases in England from the 1930s to 1970. Specifically, we explore 
how William Copeman, a dominant figure in the field in Britain from 1930 to 1970, 
led or orchestrated four translational and transformational activities—three in our 
expanded version of TM and one in the narrow bench-to-bedside mode. First, Cope-
man sought to transform general practice by disseminating best practice from spe-
cialists in a four-times updated handbook and instructive films. Second, he facili-
tated the establishment of rheumatology as an academic, research-led specialty in 
a four-times updated textbook. Third, he set out to make specialist rheumatological 
knowledge available in appropriate forms to the public in radio broadcasts, popular 
articles and books. Fourth, as we show, Copeman proved to be a pivotal figure in the 
development of innovations in the narrower sense of TM, helping to move a crucial, 
era-defining intervention—cortisone—from T1 to T4.
While we focus on Copeman’s efforts and impact, our goal is to use aspects of 
his story and his contributions to medicine to explore creatively what “translation” 
meant and now means—not to provide a comprehensive overview of Copeman’s 
career or of his role in the history of rheumatological research and practice. Our 
analysis therefore emphasises Copeman’s translational activities, by keeping the 
focus on his public work and roles as made visible to rheumatology and medicine. 
To do so, we draw especially on the published materials Copeman created and that 
reached diverse audiences: research articles, reports, textbooks, reviews, letters to 
journals, and popular media. Complementing this are archival sources (his personal 
and professional papers, along with those of societies where he played an instru-
mental role) that allow us to explore how and why Copeman set out to create these 
materials, and the effort involved in doing so. These materials allow us to show how 
and with what impact Copeman moved ideas and practices between contexts, and 
how the changes he made gained traction in those new settings.
2  William Sydney Charles Copeman
Copeman was not directly responsible for any major breakthrough in the under-
standing or treatment of rheumatic diseases, but nonetheless, his peers would 
later agree that no individual had contributed more to the improved treatment of 
rheumatic diseases or the development of the speciality of rheumatology (Porritt 
and Hart 1992). In his notes towards a biography of Copeman, his friend and fel-
low pioneer rheumatologist, Arthur (later Lord) Porritt wrote “He had the rare 
gift, by virtue of his personality, of getting new and essential things done…. He 
was a great originator, a great producer” (Wellcome Archives n.d.). Copeman was 
best known for his public role in the Empire Rheumatism Council (ERC) and 
its successor organisation the Arthritis and Rheumatism Council (ARC), and for 
lobbying for the establishment of rheumatology as a specialism, but his impact 
proved to be wider. Throughout his career he was active in research, teaching, 
clinical care, publishing, speaking, broadcasting, lobbying and organising, all 
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to further professional and public understandings of rheumatic diseases and to 
develop and extend treatments (Anon 1970a, b).
Known to his friends and colleagues as Will, William Sydney Charles Cope-
man was born in July 1900 into an established medical family. His father was 
Sydney A. M. Copeman, the country’s leading authority on smallpox vaccination, 
who had also undertaken research on other infectious diseases for the Local Gov-
ernment Board (Copeman 2004). Will Copeman trained at St Thomas’s Hospital, 
taking the conjoint diploma in 1924 and graduating MB, BChir from Gonville 
and Caius College, Cambridge in 1925. His first appointments were in paediat-
rics, at the Sorbonne in Paris, then the Hospital for Sick Children, Great Ormond 
Street, London, and at the same time at the out-patient department at St Mary’s 
Hospital, London. His work on rheumatic diseases began with rheumatic fever in 
children and developed more widely when he was appointed to be Honorary Phy-
sician at the British Red Cross Clinic for Rheumatism in London, and Assistant 
Physician at the Hospital of St. John and St. Elizabeth. As was typical for elite 
London consultants in the 1920s and 1930s, he also held part-time or associate 
appointments at other voluntary and charitable institutions: The Home for Incura-
bles, Putney, and the Star and Garter Home, Richmond, and then at the Middlesex 
Hospital when it took over Peto Place, and finally the West London Hospital. This 
spread of clinical experience and connections with patrons and governors was the 
basis for his private practice, based in prestigious Harley Street (Fig. 1). 
His medical career, like that of so many of his age, took a different turn during 
the Second World War. He was given special duties regarding rheumatic diseases 
with the British Expeditionary Force in France in the war’s early period (Cope-
man 1940). However, after Dunkirk he served as a general physician, including 
acting as medical adviser to the Malta command, from where he published on 
meningococcal septicaemia and dyspepsia (Copeman 1942; Edwards and Cope-
man 1943). His interest in bacterial infections may have come from his father’s 
work, but more likely from the role that many doctors of the time felt that infec-
tions played in the aetiology of rheumatic diseases (Coburn 1931). In 1945, 
Copeman published a review of chronic rheumatic diseases during the war, noting 
that they had been neglected relative to other health problems. However, he main-
tained that “their ‘nuisance value’ was in the aggregate considerable, even pro-
ducing a mild man-power problem in some regions, whilst the long average stay 
of hospitalised rheumatic patients aggravated bed shortages (Copeman 1946a).
After the war, and through the 1950s and 1960s, Copeman maintained appoint-
ments at the West London and Middlesex Hospitals, and at the Hospital of St. 
John and St. Elizabeth, along with his private practice. He also continued to pub-
lish extensively in journals and in textbooks that went through many editions; 
from the late 1940s, he added contributions to popular media, making the move 
into broadcasting. He even found time to write on medical history (Poynter 1971). 
Throughout this period, he also acted as the effective political leader of British 
rheumatology through his role in the Empire Rheumatism Campaign and mem-
bership of the National Health Service and Medical Research Council groups 
devoted to this specialty. As a de facto leader of British rheumatology, he also 
contributed to international organisations, as the first chair of the World Health 
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Organization’s Expert Committee on Rheumatic Diseases (Anon 1970b; World 
Health Organization 1954).
3  Specialist Practice to General Practitioners
The first of Copeman’s initiatives that could be called “translational” was his 1933 
guide for GPs The Treatment of Rheumatism in General Practice (Copeman 1933). 
He did not lack confidence. At this point in his career, Copeman had at best only 3 
or 4 years full-time rheumatological experience, yet he produced a book that aimed 
to translate and spread this newly-gained specialist knowledge to the nation’s general 
practitioners. His guide spoke to two implicit audiences: older practitioners whose 
knowledge was out of date; and new graduates who were likely to have seen very 
few rheumatic patients in their voluntary hospital-based training. Copeman was also 
clearly ambitious. He had already published in a number of journals on non-rheu-
matic subjects, such as measles, diabetes, scarlet fever, and varicose veins. It was 
only from 1930, just 5 years after graduating and coinciding his appointment to Peto 
Place, that he began to publish on rheumatic diseases. He announced his expertise 
Fig. 1  Portrait of William Copeman 1952. Seated at desk, with autograph inscription by sitter to F. 
Wrigley. Credit: Wellcome Collection. Attribution 4.0 International (CC BY 4.0)
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in a review article in the British Medical Journal (BMJ) on “Some Principles in 
the Modern Treatment of Rheumatic Diseases,” which concluded that “it appears 
more and more obvious that the intelligent combination of remedies is the keystone 
of success, the danger lying in the adoption of any one method of treatment, to the 
exclusion of the rest” (Copeman 1930).
He appears to have first acted on his aim to transform arthritis sufferers’ treat-
ment and care in a 1932 lecture delivered at the Royal Institute of Public Health, 
titled “The Control of Industrial Rheumatism” (Copeman 1932). There he set out 
a scheme for institutional innovations to improve the access of National Insurance 
(NI) patients, most of them working class, to specialist clinics and spas. At this time, 
as Cantor (1990) has shown, most cases of rheumatic disease were seen and treated 
by general practitioners, and not in hospitals. Patients fell into two groups. The first 
comprised middle and upper class sufferers, who before the NHS were mostly pri-
vate patients who could afford to pay the general practitioner’s fees and then afford 
to be referred to specialists or make visits to spas. Meanwhile, working class suffer-
ers (the second group) had a higher prevalence of rheumatic disease, because of the 
demands of industrial and manual labour, but had less access to spas and other treat-
ment facilities with only the possibility of referral if an institution with appropri-
ate specialists was nearby. In his discussion of rheumatism and the place of spas in 
interwar England, Cantor (1990) unpacks the conflict between the hospital and spa 
factions of professionals treating rheumatic diseases, showing that while they strug-
gled over priorities and resources, most clinicians had a foot in both camps.
Copeman’s plan to change the prospects of sufferers had three chief elements: 
prevention, detection and treatment. General practitioners treating sufferers with NI 
would play a primary role as illustrated in a diagram (Fig. 2).
Copeman argued that for these GPs treating national insurance patients, their role 
was diagnose, treat initially, and then route sufferers into a larger system of treat-
ment that included new centres and clinics, while also providing the individual 
patient with “general advice, and encouragement”. The presumption behind this was 
the idea that GPs were slow or reluctant to make referrals, in part because they were 
(incorrectly) pessimistic about what could be done (Editorial 1932).
Copeman’s book The Treatment of Rheumatism in General Practice (1933) elab-
orated this plan further by promoting intra-professional communication. The first 
half of the book discussed the classification, presentation and prognosis of the many 
forms of rheumatic disease, while the second half went through the treatments avail-
able across the range of presentations. His aim here was not simply to disseminate 
specialist knowledge, but to make it understandable and usable for general practi-
tioners and to do so in a succinct, accessible way that busy doctors might read. He 
would have had in mind that he was addressing some doctors who had qualified dec-
ades previously, even in the late nineteenth century, and that even those GPs eager 
to expand their knowledge had likely received little or no formal training regarding 
the rheumatic diseases. At first glance, Copeman might seem like a “know-all” elite 
physician talking down to “ignorant” general practitioners, a classic exemplar of the 
vision of science communication now widely known (and criticised) as the ‘deficit 
model’ (Turney 1998). However, his writing shows an awareness, no doubt gained 
from ample professional interactions with general practitioners, of their experience 
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and understanding, and how to address GPs productively. For instance, in this vol-
ume he was forthright about the uncertainties that still dogged specialists hoping to 
better understand rheumatic diseases, a tactic that could well have won his readers’ 
confidence and cooperation.
The book’s early chapters focused on rheumatic fever and chorea, the childhood 
forms of rheumatism with which Copeman had first developed his interest in the 
area. However, he argued that these mostly acute conditions were distinct from the 
adult forms of rheumatic disease that were chronic and disabling. Chapters on mus-
cular and neurological forms in adults came next, then the core of the book: the 
Fig. 2  Diagram of scheme for a rheumatology service. Copeman (1932 p. 986)
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arthritic diseases of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. 
In the second half, Copeman focused on treatments, first with a chapter on “Gen-
eral Aims” and then with detailed discussions of medical, dietetic, and physical 
methods, baths, colonic therapy, endocrines, actino-therapy, and orthopaedics, plus 
advice on the choice of spas, doctor-patient relations, osteopathy and “nature” cures. 
He acknowledged that the treatment of rheumatism was characterised by conflict-
ing opinions and that previously, in his own practice and writing, he had “at times 
been too dogmatic,” but he said his hope now was to present “a brief summary of all 
methods” and not to be exclusive. A final, novel feature of the book was a chapter on 
“Prognosis and End Results,” where Copeman hoped to convey the optimism under-
lying the new specialist units to general practitioners, thus converting them to the 
view that “rheumatism should no longer be considered as an ‘act of God,’ but may 
now be treated with a good prospect of success” (Copeman 1933, p. v). Review-
ers for the leading general medical publications, the Lancet and the British Medical 
Journal, both noticed and applauded this optimism. The Lancet’s reviewer praised 
the book for being both approachable and stimulating: “it spreads an atmosphere of 
restrained enthusiasm which should encourage the practitioner to attack the rheu-
matic diseases with some hope of success.” Copeman was said to have shown criti-
cal and balanced judgment, giving clear descriptions of treatments which can be car-
ried out in the home and those needing referral (Anon 1933a). The BMJ’s reviewer 
was similarly positive, stating that “Not the least valuable of Dr. Copeman’s recom-
mendations is to be found in the phrase, “the doctor approaching an arthritic case 
must train himself to do so with real hope” (Anon 1933b).
No doubt spurred by these positive reviews, Copeman’s guide sold out in a few 
months, and a second edition followed 2  years later (Copeman 1935). By then, 
Copeman had competition, suggesting a broader disciplinary push to transform atti-
tudes towards rheumatic diseases, with a number of ‘specialists’ putting their experi-
ence into print. George Kersley’s The Rheumatic Diseases: A Concise Manual for 
the Practitioner (1934) in William Heinemann’s Practitioner Series, also aimed to 
make up for the deficiencies of medical training, noting that graduates were more 
familiar with the rare diseases found in patients referred to hospitals with medi-
cal schools than the common illnesses of general practice. Matthew Ray, who also 
worked at the Red Cross Clinic, likewise published Rheumatism in General Practice 
(1934), with an endorsement from the well-known Lord (Tommy) Horder as “the 
best book on rheumatism in the English language.” Another Peto Place clinician, 
Francis Bach (1935), published on The Rheumatic Diseases: Their Treatment and 
Recognition, which was said to be more of a textbook, being “too full to appeal to 
general practitioners.” Last but not least in this rush into print came the more ency-
clopaedic Chronic Rheumatism, Causation and Treatment by Fox and van Breeman 
(1934). Clearly, Copeman had seen a market amongst GPs for both new knowledge 
about and new attitudes towards the management of rheumatic diseases.
The reviews of the second edition of Copeman’s book in 1935 again highlighted 
his ability to translate and communicate the complexities surrounding rheumatic 
diseases, which were very challenging conditions for both patient and practitioner. 
The anonymous reviewer in the BMJ noted that Copeman provided “a guide both 
as to what he can do for them within the scope of his own practice, and how he can 
1 3
Not only laboratory to clinic: the translational work of William… Page 9 of 27 35
maintain a reasonable sense of proportion in face of the astounding claims as to the 
efficacy of various nostrums which arrive by every post” (Anon. 1935). Copeman 
was quick to bring new ideas and treatments forward and in the two years between 
editions a number of new treatment modalities were added, including “gold salt 
therapy and short-wave diathermy.” He had drawn upon colleagues and specialists 
to update chapters, developing for himself a central place in professional networks 
that he utilised for his publications. In the third edition, Copeman (1939) intro-
duced more new chapters on gout and focal sepsis,1 and even more new treatments 
employing physical therapy, new compounds, and new forms of radiotherapy. The 
rapid series of editions and the considerable changes made to each were themselves 
proof to readers that rheumatology was now a field of considerable therapeutic inno-
vation, with expert leaders like Copeman willing and able to keep abreast of devel-
opments and communicate these to general practitioners. The fourth edition of The 
Treatment of Rheumatism in General Practice (1946a) also showed that knowledge 
change involved discarding theories as well as creating new ones: it was essentially 
a reprint of the third edition with the chapter on focal sepsis removed. (By the post-
war years, the idea that infections such as tooth decay and sinusitis produced poisons 
with systemic effects had gone out of fashion.)
In the late 1930s Copeman adopted a new medium to communicate up-to-date 
ideas about rheumatism, by making a silent black and white film for the Chronic 
Rheumatism Committee of the Royal College of Physicians (RCP), mostly shot at 
the Peto Clinic (Copeman 1938a, b, c). Like other specialist-made medical films 
of the era, Copeman’s film focused almost entirely on diagnosis, shown in Fig.  3 
images 3–6. Its intended audience was the general practitioner, as indicated by the 
use of medical terms in the captions, with the signs and symptoms of conditions 
illustrated by close-ups of affected joints, with features indicated by the clinician’s 
hand or pointer (Copeman himself was briefly in frame), backed up by X-rays and 
charts. The moving images of patients with different conditions imitated the style of 
instruction familiar in clinical teaching. The presentations were selective and styl-
ised because of the brevity of the sections and the absence of sound. There were 
brief illustrations of possible aetiological factors, specifically jobs and activities that 
were associated with the diseases: a policeman directing traffic with arm signals, 
gardeners digging and sweeping, and even huntsmen riding with hounds. The first 
showing was at the opening of the Rheumatism Clinic at the West London Hospital 
on 2 February 1938, and the film was screened subsequently at meetings of medical 
societies, usually in association with lectures by Copeman (Report 1938; Copeman 
1938b). The aim overall was again two-way translation: to make available expert 
knowledge to GPs and encourage GPs to refer patients to specialist units.
Copeman continued to reach out to general practitioners after the Second World 
War, first, as we have noted, with a new edition of his book and then in an article 
giving a refresher course for general practitioners on rheumatoid arthritis in the BMJ 
1 Focal sepsis refers to the common early twentieth-century view that rheumatic diseases had their ori-
gins in a localised infection and that from this toxins spread to produce systemic disease (Mollison 1920; 
Glover 1930; Hughes 1994).
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(Copeman 1952). The focus here was much more on treatment, now more widely 
available through the National Health Service, with recommendations for aspirin for 
the relief of pain, gold-salt therapy to control active disease, physical methods to 
improve mobility, and a cautious welcome for cortisone treatment (which we discuss 
in detail below). However, we must note here that soon after he also edited a book 
devoted entirely to introducing cortisone and ACTH to clinicians (Copeman 1953). 
The book’s coverage was wide, dealing with the value (or lack of it) of the new 
drugs in rheumatic conditions, plus their use in the treatment of diseases of the eye, 
endocrine system, respiratory organs, skin, blood and allergies. Lord Horder wrote 
Fig. 3  Stills from W. S. C. Copeman (1938a), Chronic Arthritis, Prepared by Dr W. S. C. Copeman for 
the R. C. P. Committee on Chronic Rheumatic Diseases, Wellcome Collection, Attribution-NonCommer-
cial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https ://wellc omeco llect ion.org/works /f8cuj tz3. 
Accessed 13 July 2020
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in the Foreword that Copeman had again produced “a practical and concise account 
of the present position [and] most skilfully assessed the value of these substances 
and their association with other forms of treatment” (Copeman 1953, p. i).
4  Rheumatology as an Academic Specialism
An explicit expectation of Copeman’s translational strategy was that better informed 
general practitioners would transfer more of their patients to specialist units like his 
own. However, he was only too aware that there were few “rheumatologists” (as 
the specialists were coming to call themselves) and specialist units, and that recent 
improvements in the treatment of rheumatic diseases had not been anywhere near 
as great as in many other areas of medicine (Weisz 2006). Thus, the development 
of rheumatology as an academic specialty was a corollary of his pitch to GPs, but 
it was important to him that rheumatology be known as a research-oriented, aca-
demic subject. In the 1930s, two organisations served as the primary vehicles for 
promoting of rheumatology as an academic specialty and transforming the special-
ty’s scale and standing. These were the ERC and the Heberden Society, and Cope-
man played a leading role in both. The ERC had been founded in 1936 with the 
seemingly omnipresent Lord Horder as chairman (Horder was at the same time also 
active in British cancer organisations and with several general medical bodies). Wil-
liam Willcox served as vice-chairman, and Copeman acted as medical secretary. In 
practice, this meant he effectively ran the Council day-to-day, organising meetings, 
establishing its public profile, and running its public appeals for funds (Witts 2004). 
The ERC’s formal aims sounded quite narrow and academic: “to organize research 
throughout the British Empire into the causes and means of treatment of rheumatic 
disease.” However, its leaders interpreted these aims broadly, to include making the 
best means of treatment available to all sufferers (Report 1936). The previous year 
the RCP had appointed a Committee on Chronic Rheumatic Diseases, which then 
produced reports for 1934, 1935 and 1936; these reports brought together a number 
of new research papers, many written by Copeman, and called further for the expan-
sion of treatment facilities (Buckley 1935, 1936, 1937). Those behind this initiative 
developed links with the ERC, principally through Copeman, and with the Ameri-
can Committee for the Control of Rheumatism, through Philip Hench at the Mayo 
Clinic who was its secretary.
Some of the elite London physicians involved with the ERC and the RCP Com-
mittee supported efforts to establish “rheumatology units” in teaching and volun-
tary hospitals, though others fought to keep rheumatic diseases in the ambit of gen-
eral physicians. Copeman, not surprisingly, supported the specialist-led version of 
practice, and successfully created two such units, first in 1937 at St. John and St. 
Stephens and in the following year, at the West London Hospital. These began as 
out-patient departments but soon acquired beds for a limited number of inpatients. 
The treatments they offered were spa-like, but there was less emphasis on water and 
more on physical methods such as massage, manipulation, splinting, and electri-
cal stimulation. They were sites also for experiments with medical treatments, as 
with gold therapy on which Copeman published in 1936 and 1937 (Copeman 1936; 
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Copeman and Tegner 1937). However, these new sites were few in number. In 1938 
in England, a few of the hospitals associated with medical schools had rheumatism 
clinics, and in rest of the country’s hospitals, which numbered over 1000, there were 
just fifty specialist rheumatism departments (Empire Rheumatism Council 1939).
The origins of the Heberden Society were in the Committee for the Study and 
Investigation of Rheumatism that had been formed at the Peto Place Clinic in March 
1936, on which Copeman was a prime mover (Copeman 1942). The society’s name 
was chosen to honour William Heberden (1710–1801), the physician who set out 
one of the earliest descriptions of rheumatism and gout. The Society initially held 
its quarterly meetings at Peto Place, where attendees read and discussed papers on 
clinical aspects of rheumatic diseases (Moll 1987). These meetings were interrupted 
by the war, but overall continued until 1983 when the Society was absorbed into the 
British Society for Rheumatology (Savage 1988).
The character of the Society’s early meetings was later described by Jonas Kell-
gren, who would himself pioneer academic rheumatology in Manchester (Dixon 
2010). Kellgren pointed to difficulties in communication, deriving from differences 
in orientation and approach, between some members:
My earliest recollection of the Heberden Society was a meeting in 1938. This 
was held in a small room in Peto Place, Dr. Heald in the chair was clearly 
a distinguished elderly physician and Will Copeman stood out from the rest 
as the keen able young physician in immaculate pin stripes and black coat. 
The remainder of the audience of some dozen people seemed to be elderly spa 
doctors who asked some rather odd questions and it seemed at this time most 
unlikely this group would develop into the fine scientific and clinical society 
that we have today (Moll 1987 p. 76).
We can see in this description the broader generational, geographical, institutional, 
and therapeutic divides amongst those treating rheumatic diseases. Stereotypi-
cally these can be characterised as young-London-hospital- and chemo-biological-
research orientated (Kellgren clearly perceived himself to be one of those) versus 
old-provincial-spa-practice and physical-treatment orientated. Copeman, though, 
would play a mediating role, despite being London- and hospital-based, with a Har-
ley Street practice and association with elite physicians at the RCP. He was the lead-
ing figure in the Chemical Sub-Committee of the RCP’s Rheumatism Campaign 
(RCP 1938), chaired by Lionel Whitby (Gardner and Tansey 2004), who had pio-
neered chemotherapy for infections with sulphonamides. Popular with his peers, 
Copeman had a record of referring his patients to other clinics that were trialling 
new treatments, such as gold and vaccine therapy, and was involved in distributing 
the ERC’s research funds (Chemical Sub-Committee 1938).
The division between urban, science-minded researchers and provincial spa-
oriented practitioners was often overdrawn by those involved for political reasons 
and while Copeman sometimes wrote of two distinct approaches to rheumatic dis-
eases (Copeman 1933), in practice he worked across them. For instance, he recom-
mended both medical and physical methods in all editions of his book for general 
practitioners, arguing for the value of both: “One of the most important therapeutic 
advances in this century is the discovery that the human body can be influenced as 
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much from the outside by what are known as Physical Methods as from the inside 
by Medical Methods” (Copeman 1946a, b). Despite later being known for his work 
around cortisone and other high-profile drugs, Copeman always advocated the use 
of occupational therapy in the treatment of arthritis and furthermore was active in 
the British Association for Physical Medicine. After the Second World War, physi-
cal medicine in Britain was reoriented to have a greater emphasis on rehabilitation, 
first with injured combatants, and then with industrial workers (Tegner 1972). This 
reorientation was mirrored by the name of the society’s journal: first in 1942, the 
British Journal of Physical Medicine added “and Industrial Hygiene” to its title, 
and then in 1947 this was replaced this with “including its Application to Industry.” 
Francis Bach, who also worked at St Stephen’s Hospital, edited a review of the field 
in Recent Advances in Physical Medicine, drawing on the expertise of 38 contribu-
tors (Bach 1950). His review featured sections on public health, and on the health of 
defined populations (school children, the Army, and industrial workers), as well as 
on rehabilitation and resettlement. In his review of Bach’s work for the BMJ, Cope-
man (1951) strongly supported Bach’s call for a new type of “physical-medical spe-
cialist,” in what he saw as an “infant specialty.”
Copeman himself, though, was not to be a member of this “infant specialty”. 
Rather he increasingly committed himself to the development of rheumatology 
as a disease-defined, academic-medical specialty, one that was based primarily in 
medical schools and hospitals. He hoped such a specialism would overcome existing 
divisions and raise the status of the field. A common sign of aspirations like these 
is the creation of a journal, and Copeman also engaged in this. In the mid-1930s, 
the Annual Reports of the RCP’s Committee had served as a nascent journal, and 
when these ceased, the ERC took over and carried on the mission formally. In 1939 
the first volume of The Rheumatic Diseases was published, though its title would 
soon become Annals of the Rheumatic Diseases. This new journal was edited by 
Charles W. Buckley, in collaboration with Copeman and Alfred G. Timbrell Fisher 
and published quarterly (Anon 1955a, b; W. A. L. 1968). Buckley was in one sense 
a traditional spa doctor, in that he worked at the Devonshire Hospital for Rheumatic 
Diseases in Buxton, but unusually he was also Fellow of the Royal College of Phy-
sicians and active in the ERC. Timbrell Fisher, meanwhile, also straddled the sup-
posed gulf between spa doctors and urban specialists: an orthopaedic surgeon at St 
Stephen’s Hospital, in the1930s he had published on the viral origins of rheumatic 
disease, but he would be best known for his work on the manipulation of joints 
(Fisher 1991). In the journal’s early years, its articles focused chiefly on the aetiol-
ogy of rheumatic conditions (especially possible bacterial and viral causes), their 
pathology and morphology, and on serological markers of disease. There were no 
articles on treatment, suggesting a research rather than clinical focus. The journal 
continued to be published through the Second World War, and its editorial team 
would soon be supplemented by Mervyn H. Gordon and two American associate 
editors: Philip Hench and Loring Swaim.
The Second World War provided Copeman and others like him with the oppor-
tunity to publicly, professionally and politically promote rheumatology as a clini-
cal specialism of national importance. It also brought challenges, as when in 1939, 
Copeman was put on general medical duties rather than expected to continue with 
 M. Worboys, E. Toon 
1 3
35 Page 14 of 27
his specialist work. Nevertheless, in July 1940 he gave a talk, “Notes on Treatment 
of the Rheumatic Diseases in the B.E.F,” that continued to push his vision for rheu-
matology’s organisation. There, he called for centralised, specialised units to provide 
the best treatment for troops on the frontline in order to avoid conditions becoming 
chronic and loss of personnel. He also argued that such units offered economies of 
scale, and “what is perhaps of greater importance, it would stimulate interest in this 
type of case, which does not exist widely to-day, in spite of the high incidence of 
these diseases” (Copeman 1940, pp. 384–385).
An important part of the ERC campaign was its annual publication of A Plan for 
National Action. This at last bore some fruit when, thinking about post-war health 
service planning, the Ministry of Health set up a sub-committee on rheumatic dis-
eases. Hopes were thus high, after the passage of the National Health Service Act in 
1946, that when the new service began rheumatology would enjoy new support and 
status. After all, in the years leading up to and after the start of the NHS, there were 
many reports by professional bodies and government committees on the need to 
develop rheumatology services. However, there ended up being no central direction 
for these efforts and it was left to regional and local bodies to act. Some did estab-
lish departments or centres, but most did not, with the innovators being in northern 
cities (Leeds, Manchester, Sheffield) and in familiar London hospitals (West Lon-
don, Hammersmith, Royal Free), but in most places hopes that specialist posts or 
specialist departments would be created were dashed (Horder 1953). Those calling 
for specialist posts and units faced opposition from those working in physical medi-
cine and their technique-based practice, and from general physicians as the develop-
ment of drug treatments had normalised the management of rheumatic diseases to 
their style of practice.
In 1945, Annals became the official publication of the Heberden Society, with 
the editorial committee remaining the same and with Copeman joining a new Edito-
rial Committee in 1947. In marking its formal association with the ERC, Buckley, 
who was then the President of the Society, stressed that now “its primary object 
[was] the study of the clinical aspects of rheumatic disease,” but saw no conflict 
with the research orientation of the ERC. Indeed, Buckley questioned “whether any 
group of diseases has suffered more from methods of treatment devised without any 
consideration of the underlying pathology responsible for the symptoms presented” 
(Buckley 1945). None the less, the Society was social as well as expert, being quite 
traditional. It had special regalia, many types of honours, high class dinners, and a 
historical library. It was the ideal arena for networking and Copeman was a central 
figure, making its library a great resource and professional hub.
Copeman further cemented his place as the leader of academic rheumatology in 
1948 when he brought together what he termed “a galaxy of talent” to contribute 
chapters to a Textbook of Rheumatic Diseases (Copeman 1948). The edited volume 
covered all forms and all aspects, from aetiology and pathology, to prevention, treat-
ment and aftercare. At the centre of the book were eleven chapters on individual 
rheumatic diseases, which dealt again with all aspects of each condition. There were 
just four on physical medicine: i.e. radiotherapy, physiotherapy, hydrotherapy and 
spa treatment. The contributors were the leading clinicians in the field and mostly 
(seventeen out of twenty-four) from London hospitals. Only three of the remaining 
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seven contributors were from provincial spas, including Buxton’s Buckley and 
Bath’s George Kersley. Copeman wrote the introductory chapters on nomenclature 
and classification and the history of the disease, and two other clinical chapters on 
chorea and fibrositis. Reviewing the text for the BMJ, Kenneth Stone highlighted its 
presumed audience, noting that it was “intended to be a textbook for those young 
medical men who have decided to embark on a specialist career in the rheumatic 
diseases” (Stone 1948). However, his assessment, no doubt coloured by the recent 
publication of his own book Diseases of the Joints and Rheumatism (Stone 1947), 
offered only faint praise: while Copeman’s textbook was “a very good book of its 
kind” and “superbly produced, profusely and well-illustrated,” Stone wrote, with 
twenty-four authors it was “not a textbook but a symposium, with the inevitable rep-
etitions and sense of discontinuity” (Stone 1948). Other reviewers disagreed: when 
the second edition was published in 1955, the Journal of Bone and Joint Surgery’s 
reviewer praised the volume as “an outstanding achievement” (Capener 1955).
The major addition to this second edition was endocrinology, where a new chap-
ter by Oswald Savage reflected “the major advances which have resulted from the 
discovery of the action of Cortisone, Hydrocortisone and ACTH.” As Copeman 
explained in the preface, these major advances had developments also led to “the 
complete rewriting of several chapters,” indicating that the new approaches were 
being incorporated and translated across many areas of practice (Copeman 1955, 
p. v.). These efforts paid off: one reviewer noted that the volume had “deservedly 
secured its place as a standard textbook,” another regarded it as “the” reference work 
(Anon 1955a, b; Lawrence 1956). The new steroids as well as other drugs and com-
pounds, such as gold, phenylbutazone, and aspirin, were considered across several 
chapters. This shift rebalanced the textbook’s content to decisively emphasise medi-
cal over physical approaches, and foretold a laboratory-led, pharmaceutical future 
for therapy.
The shift to medical approaches continued in the third edition of Copeman’s text-
book in 1964. A review by Jeffrey (1965) noted that, “Compared with its predeces-
sor, the third edition of Dr. Copeman’s textbook has grown by 80 pages and half 
a pound in weight,” despite the use of smaller type. Jeffrey welcomed the timing, 
as the innovations in treatment of the late 1940s and 1950s now had “fallen into 
reasonable perspective.” The chapter on radiotherapy was withdrawn, there being 
“no well-defined field for such therapy with the rheumatic diseases.” Copeman’s 
comprehensive coverage meant that the chapter on hydrotherapy remained, though 
largely unaltered, while there were new chapters added on auto-immunity and genet-
ics. This breadth made the Copeman textbook, in its many editions, stand out as a 
contribution to the field and not only in Britain. In 1970, Gabor Inke, a New York 
anatomy professor, sent a questionnaire sent by to medical schools to determine “the 
most frequently recommended medical textbooks” (Inke 1971). Respondents men-
tioned the third edition of Copeman’s textbook, one of only three volumes (of thirty-
four listed) to cover rheumatology.
The fourth edition of the textbook (Copeman 1969) was produced just 4  years 
later, prompted by the need to add “further advances … in the fields of biochem-
istry, auto-immunity, cytology and genetics,” plus changes in surgery and new epi-
demiological information. There was a changing of the guard, with many stalwart 
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contributors absent, notably H. A. Burt, Mervyn J. Gibson, B. Schlesinger, William 
Tegner and Sir Reginald Watson-Jones, who had all contributed to the three previous 
editions. The replacements were the new elite: D. L. Gardener, head of the Kennedy 
Institute, Allan St. J. Dixon, Clifford F. Hawkins, Stephen Mattingly, Emmanuel 
Miller and James T. Scott. Still contributing nearly 20 years on were H. Osmond 
Clarke, Henry (now Lord) Cohen, D. V. Davies, Campbell Golding, Jonas Kellgren, 
George Kersley, Oswald Savage, and the editor. While much was new, Copeman 
retained his chapter on non-articular arthritis rheumatism, even though the last cited 
reference was to a paper published in 1954. Indeed, the condition was becoming an 
increasingly contested diagnosis; on the one hand it was being redefined as fibromy-
algia and on the other its status as a rheumatological condition was disputed alto-
gether. One view was that it was a “medically unexplained somatic syndrome,” that 
belonged to mental health rather than rheumatology. Indeed, its status continues to 
be debated in the twenty-first century as the “fibromyalgia wars” (Wolfe 2009). Nev-
ertheless, the durability of Copeman’s textbook in academic rheumatology was evi-
dent when two further editions, with his name in the title, were published after his 
death (Scott 1978, 1986). By that point, Copeman’s drive to remake rheumatology 
as an academic, research-led specialism, one committed to producing new specialist 
knowledge that could be translated to general practitioners and employed in every-
day practice, had been achieved.
5  Rheumatism and the public
In 1947, Copeman had been one of the founders of another organisation lobbying 
for the support of rheumatic disease: the British Rheumatism Association (BRA), 
meant as a complement to the ERC. BRA allowed public membership and set out to 
perpetuate the pre-war tradition of voluntarism in convalescence, by founding what 
were called “Horder Homes” (to teach sufferers how to cope best with their condi-
tion) and by recruiting “Horder Helpers” to work between home and hospital. But 
the Association focused mostly on attracting public attention to pain relief, physical 
treatment, and assistive devices and services for the rheumatic patient, as evidenced 
by at an early meeting (September 1949) where:
Some 15 firms had stands displaying preparations for the relief of rheumatic 
disorders, electro-medical apparatus, invalid furniture and transport, and 
devices for occupational therapy. There were also displays illustrating spa 
treatment, home and after care visiting, and industrial rehabilitation (Report 
1949).
Copeman, however, struck a somewhat different note at this meeting, by speak-
ing enthusiastically about a laboratory-sourced treatment, which he referred to as 
an “epoch-making announcement.” This was, of course, Compound E, soon to be 
renamed cortisone (Report 1949), and its announcement would (in retrospect) lead 
the takeover of pharmaceutical approaches in the treatment of rheumatic diseases. 
But Copeman did not only promote cortisone; he also made the most of the oppor-
tunities the announcement of this “epoch-making” drug opened for promoting a new 
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rheumatology. He did so in two ways: first, by building on the news splash around 
cortisone to develop new opportunities for public engagement, considered in this 
section, and second, by leading the clinical trials facilitating introduction of the drug 
in Britain, which we consider afterwards.
On 3 May 1950, billed anonymously as “a doctor,” Copeman (1950a) began a 
series of eight 15-min weekly talks on “Rheumatism” for the BBC’s Home Service. 
(This anonymity was expected by professional ethics at the time, as doctors were 
supposed to eschew anything that smacked of advertising or naked self-promotion, 
though they could speak on behalf of their organisations. This would begin to change 
a decade later.) The “Rheumatism” series was a didactic “public information” medi-
cal broadcast typical of those given in the late 1940s and early 1950s (Karpf 1988; 
Loughlin 2005; Nathoo 2009, 33–56; Jones 2013). The talks existed in the first place 
due to Horder’s long-time lobbying, as he had broadcast radio appeals for support of 
rheumatic disease (and other diseases) from the late 1920s onward (Horder 1928). 
Copeman’s stated aims, though, were somewhat different. He focused not on raising 
funds but on allaying the fears of sufferers and giving hopeful grounds for relief; on 
informing a larger public of the scale of the rheumatism problem and the need for 
early investigation of any symptoms: and on promoting the ERC as the organisation 
responsible for shaping public discourse about rheumatism. The first talk, “What 
is rheumatism?” promised the listener he or she would learn “what can be done for 
you, and what you can do yourself if you are a sufferer.” The seven following broad-
casts addressed the main areas set out by the RCP Committee in the 1930s (rheu-
matic fever and heart disease; fibrositis, sciatica and neuritis, rheumatoid arthritis, 
osteoarthritis, arthritis of the spine and gout, and rheumatism research) and then 
Copeman finally asked “What of the future?” The talks were gathered in a pamphlet 
which was published by the ERC in August 1950, and then reprinted a further five 
times that year.
A virtue of Copeman’s broadcasts was his empathy with the suffering of affected 
listeners, which was likely to have been common as, at the end of the first broadcast, 
he highlighted that three million working weeks were lost every year, with these 
enduring and frustrating conditions. In the third talk, Copeman discussed lumbago 
or backache, the most common and popular terms for “rheumatism,” which he 
explained was fibrositis—a condition of muscles rather than joints. The complaint 
was associated with particular occupations that involved prolonged lifting or bend-
ing, or “may come on for no apparent reason—in you or me as we jump blithely out 
of bed one morning.” Relief might be spontaneous and if not, he recommended aspi-
rin or bathing in hot water. Recognising how few homes had bathrooms, Copeman 
set out other domestic “physical” remedies that did not require access to a bathtub: 
“place the patient on his face and put a piece of brown paper over his back. With this 
to protect his skin a really hot domestic iron can be run over his back to ‘iron out the 
pain’ as they say.” In persistent cases, doctors might recommend massage, electrical 
treatment, injection of local anaesthetics, support plasters, or a belladonna plaster. 
To lighten the narrative, Copeman turned to history, noting the impact of the condi-
tion on British history: Wellington was only in command at Waterloo because he 
had been sent back from India where he had been “a martyr to lumbago.” The next 
talk was on sciatica (slipped disc) and neuritis, followed by three talks on arthritic 
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conditions. In the final talk on “Rheumatism Research—What of the future?”, he 
discussed cortisone, bemoaning how it had been boomed by the press when it was 
still in trial and supplies were very limited. Copeman endeavoured to give listeners 
a better appreciation of medical research as he understood it with a military analogy. 
He said that the experimental work on cortisone had “established a deep ‘beach-
head’,” but time was needed for this to link up with “the main body” of medical 
knowledge (Copeman 1950, p. 46). His entrance into broadcasting was a success, 
and opened further doors: in subsequent years, Copeman became a regular on the 
Home Service, giving talks on rheumatic diseases in programmes such as “Science 
Survey,” “European Science,” and “Woman’s Hour” (Copeman 1950–1954, Box 6).
In 1954, with Richard Mason, Copeman returned to print with a popular book 
on rheumatism for Duckworth’s popular Modern Health Series, edited by Thomas 
Horder. The series aimed
to give precise, authoritative information; to take the patient into the doctor’s 
confidence …; to better explain simply and intelligibly; to offer sufferers what-
ever hope the most up-to-date medical knowledge can honestly offer; in short 
to tell the truth about disease as it has never been told to the general public in 
print before. (Horder 1954–1957)
This description included several “translational” actions: “to better explain simply 
and intelligibly,” “to offer sufferers … the most up-to-date medical knowledge,” and 
“to tell the truth.” The other books that launched the series were similarly framed 
and were on subjects as varied as heart disease, varicose veins, and epilepsy; others 
followed on tuberculosis, skin diseases, cancer and allied diseases, childbirth, dia-
betes, and foot troubles. Readers were reminded the books were “designed to give 
general background” and were “not courses of self-treatment”.
The opening epigram in Copeman’s and Mason’s book was from the writing of 
the orthopaedic surgeon G. R. Girdlestone and reiterated the importance of morale 
as well as medicine in treatment: “Don’t try and live as though you were quite well, 
but never lose hope. It isn’t what happens to you that matters. It’s how you take it!” 
(Copeman and Mason 1954, p. 8) However, the overall message of the text itself 
was much more positive about the possibilities of a new and research-led medicine: 
there was much that medicine could do, especially if sufferers sought early treat-
ment. Indeed, Copeman and Mason stated, it was vital “to dispel the most damaging 
factor—the feeling that nothing can be done.” Again, the aim was to convert suffer-
ers into patients, describing common symptoms and interpreting to be treatable by 
modern medicine. The discussion of each rheumatic condition was similar to that in 
his 1950 talks, though there were more historical references, reflecting Copeman’s 
growing interest in the subject. The final chapters were the most practical, on “What 
the National Health Service Provides” and “’Gadgets’ Which Help.” Unsurprisingly 
given his position in the ERC, Copeman was clear that while the NHS now offered 
sufferers more than was available before 1948, it was not enough and there was 
much more both government and charities could do.
When he succeeded Horder as the head of the ERC in 1955 and remained at 
its helm when it became the Arthritis and Rheumatism Council (ARC), Copeman 
became the public face of British rheumatology. He fronted most the Council’s 
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appeals for funds in print, on the radio and eventually on television, asking for dona-
tions to continue its work in transforming the lives of sufferers. Together with the 
BRA (which later became the BRAA or British Rheumatism and Arthritis Asso-
ciation), the ARC launched “Arthritis Month” in June each year to raise the pub-
lic profile of its work. Copeman’s strategy for gaining attention and support was to 
translate patient suffering into an economic cost, which brought headlines such as: 
“£80 Million Lost from Rheumatism,” “‘Startling Figure’ on Arthritis,” and “Rheu-
matism’s Toll of Work Time” (Report 1961, 1962a, b). He also lost no opportunity 
to lobby for rheumatology more widely, especially for it to be given NHS resources. 
In 1969, he queried the spending priority given to heart transplants, contrasting 
the high profile (and high costs) of these interventions with the relative neglect of 
rheumatic diseases, which were much more common, caused greater suffering, and 
would give greater returns for many more sufferers (Roper 1969). Four years ear-
lier, he had even seized on a discussion about the government’s decision to find the 
money to keep a Cezanne painting in the country, noting that by contrast the govern-
ment gave little attention to research on rheumatic diseases (Report 1965). In other 
words, throughout this pivotal period Copeman either found or created new opportu-
nities to promote his vision of how rheumatological knowledge could be produced, 
transferred, and applied. Whether he directly addressed the public or engaged in 
political lobbying, he spent his time translating his clinical knowledge and experi-
ence to practical ends, endeavouring to “sell” the value of rheumatology at all levels, 
from the individual up to the economy.
6  Laboratory to clinic
So far we have focused on the importance of translational activities other than from 
laboratory to clinic. But now we turn to briefly consider Copeman’s work in that 
area, which was very significant indeed. As mentioned above, Copeman’s move into 
radio broadcasting had been linked to a clinical research project, namely working 
with cortisone. He led British trials with the drug, which as a number of scholars 
have shown, was regarded as the most important turning point in the treatment of 
rheumatic diseases in the twentieth century (Rodnan and Benedek 1970; Marks 
1992; Cantor 1992, Hetenyi and Karsh 1997; Dixon 2000; Benedek 2011, Haller 
2012). But Copeman was in the prime position for this role because of the activ-
ities discussed above. It was also an opportune moment. In his history of British 
rheumatology, Dixon (2000, p 15) suggests that 1948 was an annus mirabilis for 
the specialism, citing the general optimism due to the creation of the NHS and the 
wider availability and impact of antibiotics, along with specific developments such 
as the discovery of the rheumatoid factor (a diagnostic antibody) and the introduc-
tion of the anti-inflammatory drug Irgapyrine, which contained a future therapy 
for arthritis, phenylbutazone (Worboys and Toon 2018). However, in hindsight the 
most important events were the early reports from the United States of compound E, 
developed by Philip Hench at the Mayo Clinic.
Copeman had had previous contact with the Mayo group, especially from 1942 
onwards when Hench, who published frequently in the journal, became an associate 
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editor of Annals. Most significantly, the October 1948 issue of Annals had included 
the oration Hench gave to the Heberden Society that year, in which he reviewed the 
work that led to the investigation of adrenal hormones and compound E. Later, the 
June 1949 issue of the Annals had a scoop: it was the first mainstream rheumatology 
journal to reproduce the paper announcing compound E, a paper that had previously 
only appeared in Proceedings of the Mayo Clinic, a publication that was not widely 
available. An accompanying editorial, most probably written by Copeman, presci-
ently predicted that, “Apart from its effect in treatment, [cortisone] will stimulate 
research in many directions which may produce results of the utmost importance” 
(Editorial 1949).
Copeman and Oswald Savage, his colleague at the Middlesex Hospital, vis-
ited the Mayo Clinic in 1949 and 1950 to learn about compound E. On the sec-
ond occasion, Savage was given “a small supply” by Hench, which was used in the 
first English trial, in a study funded by the Medical Research Council and the Dan 
Mason Research Foundation of the West London Hospital (Copeman et al. 1950). 
The American findings were confirmed: the drug gave remarkable relief of symp-
toms, returning good mobility to sufferers previously immobilised. However, it only 
relieved symptoms; it was not a cure. Symptoms returned when the drug was with-
drawn, which in some cases had been prompted prematurely by adverse reactions 
(Worboys and Toon 2019).
Copeman’s group at the Middlesex published a number of articles on the new 
drugs based on cases they had treated (Copeman et al. 1952; Copeman and Savage 
1953). More significantly, based on this experience, Copeman was made chair of 
the Medical Research Council’s steroid committee, which controlled the distribution 
of the limited supply of the available drugs and supported clinical trials, adopting 
the then-novel double blind clinical trial protocols advised by Austin Bradford Hill 
(Bradford Hill 1952; Marks 1997; Bothwell and Podolsky 2016). The main trial, 
supported by the Medical Research Council (MRC) and the Nuffield Foundation 
compared cortisone and aspirin, the latter “another drug usually regarded as effi-
cacious in relieving symptoms and in improving the patient’s functional capacity” 
(Joint Committee 1954). The conclusions, published in May 1954, were surprising 
to say the least. The trial found that “For practical purposes … there appears to have 
been surprisingly little to choose between cortisone and aspirin in the management 
of these 61 patients in the early stages of rheumatoid arthritis” (Joint Committee 
1954, p. 1227). This bombshell finding was reported widely in the national press 
under headlines such “Aspirin Maybe Best” and “Aspirin Equals Cortisone” (Anon 
1954a, b). A second report published in September the following year, confirmed 
the findings on equivalence of cortisone and aspirin (Joint Committee 1955). These 
were important findings as cortisone, while relieving symptoms, produced a number 
of serious side effects, whereas the benefits and risks of aspirin were well known. 
The controlled and limited introduction of cortisone, due initially to shortages in 
supply and costs, turned out not to have been as disadvantageous to British patients 
as previously thought, as the main alternative appeared just as good but with fewer 
risks.
The response of the pharmaceutical industry to the problems with the supply and 
toxicity of cortisone was to search for new versions, with fewer risks and greater 
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efficacy in mitigating symptoms (Worboys and Toon 2019). These efforts were suc-
cessful and led to a new class of drugs, the corticosteroids, the most favoured of 
which in the late 1950s were prednisone and prednisolone. Copeman and his col-
leagues at the West London Hospital conducted trials on these new drugs, not so 
much with RCTs but clinic-based, case reports on groups of patients, following on 
from trials in the United States. Meanwhile, Copeman continued to lecture and pub-
lish across medicine, as he had for the public sphere, on corticosteroids, speaking as 
the country’s leading clinical researcher and research organiser on the subject. His 
full and detailed reports to these various audiences were themselves acts of transla-
tion: he translated clinical research results into terms that helped his peers under-
stand the benefits and risks of this new class of drugs, particularly by comparative 
framings with other treatments and with cases from his own clinical practice.
Nearly a decade on from the debut of compound E, Copeman reported that with 
rheumatoid arthritis, steroid therapy was only valuable in the minority of cases that 
did not respond to “classical and conventional methods, including physiotherapy” 
(Copeman 1958). Similar studies in centres across the country came to the same 
conclusion (Duthie et al. 1955). Nonetheless, Copeman explained that with certain 
patients “steroid therapy can make the difference between crippledom and pain-
less independence,” providing doctors closely supervised patients to monitor side-
effects. He was less positive about prednisone and prednisolone than many of his 
colleagues, but was confident that further research would produce “a substance 
whose action is confined entirely to the requisite therapeutic properties, without 
unwanted side-effects” (Copeman 1958, p. 176).
Copeman’s many roles enabled him to continue to foster research, but leadership 
was taken up by a new generation. In October 1963, he gave up the Chairmanship 
of the ERC, being promoted to the position of President (Report 1963). The new 
Chairman, Viscount Knollys, oversaw immediate changes. The ERC became the 
Arthritis and Rheumatism Council (ARC) and there was a new push to fund labora-
tory research, with a major investment in the Kennedy Institute of Rheumatology, 
then at the West London and Charing Cross Hospitals (Report 1964). In 1961, Mrs 
Mathilde Kennedy, the younger sister of Sir Simon Marks and part-heir to Marks 
and Spencer, gave £500,000 [£12 M in 2019] to fund a research centre in rheumatol-
ogy (Report 1962a, b). Copeman led attempts to find a host institution in London, 
which proved difficult as most regarded such a centre as a burden rather than a boon. 
The Charing Cross Hospital agreed to take it on, only to renege on the promise. 
Eventually, the Hammersmith Hospital agreed, stipulating that a revenue stream of 
£200,000 over 5 years be found. A request was made to the ARC and turned down. 
Copeman then intervened, using his new post a chair of the Council’s Research 
Committee to secure the necessary support. The Kennedy Institute opened in Octo-
ber 1966, with a two-page spread in the Times, with, unsurprisingly, a lead article 
by Copeman, and others by Savage, Duthie, Lord Knollys and Dugald Gardiner, 
the Institute’s first director. The Institute occupied a newly built, six-storey build-
ing with clinical research facilities, including an out-patient clinic, and laboratories 
for morbid anatomy, biochemistry, immunology, bacteriology, cellular biology and 
experimental pathology (Dixon 2000; Anon. 1964). Copeman remained chair of the 
Kennedy’s management committee until his death in 1970.
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7  Conclusion
This article has used the career and work of William Copeman to contend that there 
are important “translational” activities in medicine other than those of laboratory 
origin, and thus that the hegemony of the “bench to bedside” shorthand for TM can 
limit our understanding of the sources of change in clinical medicine. Copeman’s 
efforts highlight the importance of the translation, transfer and transformation of 
knowledge and practice in three neglected areas: from specialists to general prac-
titioners; from researchers to students and practitioners through the development of 
academic specialisms; and from doctors to patients and the public. Perhaps most 
importantly, for Copeman and for others like him, all these forms of translations 
came as a package, where each supported and extended the others. We discussed 
Copeman’s work in what would traditionally be considered TM, bench-to-bedside 
work on cortisone and corticosteroids in clinical application and trials (T2), at the 
end of this article, because his story reminds us that translation of clinical knowl-
edge does not necessarily begin with a single drug embodying a concept, but with 
the activities of those who produce knowledge through and around it, and who in 
most cases have been doing so for some time before the drug appears.
It is impossible to give a quantitative estimate of the impact of Copeman’s activi-
ties in the translations and transformations that we have discussed. This is because 
all involved multiple, interacting factors that changed over time, in part as a result of 
Copeman’s goals of transforming all aspects of practice in rheumatology. However, 
his enduring leadership role in many organisations would suggest that he was highly 
influential. In their appreciation of Copeman’s importance in contemporary medi-
cine, Porritt and Hart write that “He was seldom entirely sure he was in the right, 
would ask others their opinion and … usually act upon it.”2 In terms of rheumatol-
ogy as an academic specialism, both his handbook for general practitioners and his 
textbook sold well, each going through four editions. For nearly 40 years he was the 
most important gatekeeper in British rheumatology, though the term does not do his 
work justice. He did much more than control the flows of knowledge, he tailored the 
presentation of ideas and practices to suit the needs and interests of different groups. 
Nor was he alone in this kind of work: readers familiar with the mid-century history 
of biomedicine and medical specialism will likely know of other professionals who 
occupied similar roles in other areas (for instance, see Cantor 2002; Toon 2007 on 
cancer in Britain). Copeman exemplified an era in clinical research where in efforts 
to produce new knowledge about disease and new structures for investigating and 
treating disease overlapped and interacted with efforts to produce new public under-
standings and experiences of disease.
The 1950s were Copeman’s most influential decade, when he was active with all 
four types of translation. Due to his standing already, from two decades of lead-
ership, he was well placed to take a leading role in introduction of cortisone. In 
his writings on the subject, he was always clear that bench to bedside was never a 
2 Porritt and Hart, “W. S. C. Copeman,” (1992, 285).
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singular or simple process, rather there had to be “continual investigation,” which 
we would term translation and retranslation, to determine the most effective and 
safest treatments, in a landscape where patient profiles, available drugs and trials 
protocols were constantly changing. From the 1950s, Copeman’s activities became 
increasingly focused on the ERC and seeking the establishment and expansion of 
rheumatology in the NHS, with the goal of a network of clinicians and specialist 
departments covering the country. In the years leading up to, and after the start of 
the NHS, there were many reports, by professional bodies and government com-
mittees on the need to develop rheumatology services, almost all of which were 
about encouraging the transfer of patients from GPs to specialists and better inform-
ing GPs and the public of the possibilities of the new specialism. At the end of the 
1950s, there had been little progress (Dobson 1958; Copeman 1958). A further 
10 years on, Copeman was still complaining about the absence of special units for 
a class of diseases that caused, arguably, the greatest suffering and economic losses 
for individuals and the country (Report 1967a, b). Rheumatology as an academic 
specialism, aided by dedicated ERC and ARC funding and pharmaceutical innova-
tions, had flourished, but rheumatology as a clinical specialism remained marginal. 
The reasons for this lie beyond this study, but Copeman’s translational activities give 
clues. He was always emphasising the personal, social and economic costs of rheu-
matic conditions, the implication being that chronic diseases, which disproportion-
ately affected the elderly and women, had not moved to the centre of medical policy, 
and were yet to attract public investment they deserved. In hindsight, we can say that 
the end he was seeking was the transformation of health services and medical work 
to best meet the challenges of a new world of disease, one where chronic diseases 
had become much more important.
While we have advocated a wider conception of “translation” and “translational” 
activities in medicine, our analysis can still be seen in terms of the conventional 
four-stage TM process. We are, however, arguing for much more focus on clinical 
implementation and uptake—T3, in other words for the transformation of clinical 
practice and effectiveness. Studies of industrial innovation no longer frame “imple-
mentation and uptake” teleologically as passive and one-way, but as active adoption, 
involving adaptions and change, with reciprocal impacts on practice at all levels and 
on social relations and institutions. Thus, Copeman’s first translational endeavours 
with general practitioners had the goal of changing the knowledge and culture of 
general practice. They aimed to make doctors better informed, open to change, more 
confident in referrals, and more optimistic with patients about treatment. The pro-
motion of academic rheumatology was about establishing research-focused cadres of 
specialists, keeping medical schools and hospital practice up to date and encourag-
ing innovation. Finally, Copeman believed an informed public would be more will-
ing to seek early treatment and comply with advice, benefiting themselves and mak-
ing doctors’ task easier. This would have increased demand for specialist services 
and, of course, should have encouraged donations to charities. In short, studies of 
Translational Medicine and “translation” in medicine should not confine themselves 
to documenting and promoting processes of technical change. Instead, we think they 
would profit from a wider view of the many, multiple kinds of work that have been 
necessary to accomplish transformation.
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